Incessant monomorphic ventricular tachycardia induced by the proarrhythmic effect of amiodarone

Internal Medicine

Volumn 50, Issue 21, 2011, Pages 2591-2595

  Makimoto, Hisaki ^a   Noda, Takashi ^a   Kurita, Takashi ^a   Nakajima, Ikutaro ^a   Yokoyam, Teruki ^a   Doi, Atsushi ^a   Yamada, Yuko ^a   Okamura, Hideo ^a   Satomi, Kazuhiro ^a   Aib, Takeshi ^a   Shimizu, Wataru ^a   Suyama, Kazuhiro ^a   Aihara, Naohiko ^a   Kamakura, Shiro ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Amiodarone; Class III antiarrhythmic; Monomorphic ventricular tachycardia; Proarrhythmia; Torsade de Pointes

Indexed keywords

AMIODARONE; NIFEKALANT; SOTALOL;

ADULT; ARTICLE; CARDIOMEGALY; CASE REPORT; CLINICAL EVALUATION; COLD SWEAT; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; FAMILY HISTORY; FEMALE; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MONOMORPHIC VENTRICULAR TACHYCARDIA; QRS COMPLEX; QT INTERVAL; SINUS RHYTHM; THORAX RADIOGRAPHY;

AMIODARONE; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; TACHYCARDIA, VENTRICULAR;

EID: 80455129356     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5588     Document Type: Article

References (11)

1. Vassallo P, Trohman RG. Prescribing amiodarone. JAMA 298: 1312-1322, 2007.
2. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 106: 788-797, 1983.
3. Hohnloser SH, Klingenheben T, Singh BN. Amiodaroneassociated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121: 529-535, 1994.
4. Brown MA, Smith WM, Lubbe WF, Norris RM. Amiodaroneinduced torsades de pointes. Eur Heart J 7: 234-239, 1986.
5. Goldschlager N, Epstein AE, Naccarelli GV, et al; Practice Guidelines Sub-committee-North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 4: 1250-1259, 2007.
6. Kusano KF, Hata Y, Yumoto A, Emori T, Sato T, Ohe T. Torsade de pointes with a normal QT interval associated with hypokalemia: a case report. Jpn Circ J 65: 757-760, 2001.
7. Geng DF, Jin DM, Wang JF, Luo YJ, Wu W. Clinical study of amiodarone-associated torsade de pointes in Chinese people. Pacing Clin Electrophysiol 29: 712-718, 2006.
8. Tomlinson DR, Cherian P, Betts TR, Bashir Y. Intravenous amiodarone for the pharmacological termination of haemodynamicallytolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg Med J 25: 15-18, 2008.
9. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med 47: 217-224, 2006.
10. Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Acad Emerg Med 17: 297-306, 2010.
11. Duff HJ, Stemler M, Thannhauser T, Laganiere S, Rude E, Lester W. Proarrhythmia of a class Ic drug: suppression by combination with a drug prolonging repolarization in the dog late after infarction. J Pharmacol Exp Ther 274: 508-515, 1995.